Loading…
Increasing plasma ADAMTS13 activity is associated with HBeAg seroconversion in chronic hepatitis B patients during 5 years of entecavir treatment
The relationship between hemostatic system and HBeAg seroconversion (SC) of chronic hepatitis B (CHB) patients is ill-defined. We therefore evaluate the predictive value of plasma ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin motif repeats 13) and VWF (von Willebrand factor) fo...
Saved in:
| Published in: | Scientific reports 2019-04, Vol.9 (1), p.5916-5916, Article 5916 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c474t-419326ac45ba9454d4a6dcd93f6582abeec944f0a9aad7f9c850f040787294d03 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c474t-419326ac45ba9454d4a6dcd93f6582abeec944f0a9aad7f9c850f040787294d03 |
| container_end_page | 5916 |
| container_issue | 1 |
| container_start_page | 5916 |
| container_title | Scientific reports |
| container_volume | 9 |
| creator | Guo, Renyong Xie, Yirui Yang, Jiezuan Lu, Haifeng Ye, Ping Jin, Linfeng Lin, Wenqin |
| description | The relationship between hemostatic system and HBeAg seroconversion (SC) of chronic hepatitis B (CHB) patients is ill-defined. We therefore evaluate the predictive value of plasma ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin motif repeats 13) and VWF (von Willebrand factor) for CHB patients during 5-year entecavir (ETV) treatment. One hundred and fourteen HBeAg positive CHB patients on continuous ETV treatment were recruited. Liver biopsies were evaluated using the METAVIR scoring system, and plasma ADAMTS13 activity (ADAMTS13: AC) and VWF antigen (VWF: Ag) were determined at baseline, 3, 12, 24, 36, and 60 months, respectively. ETV treatment resulted in an increased ADAMTS13: AC and decreased VWF: Ag (both
P
|
| doi_str_mv | 10.1038/s41598-019-42421-5 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6459868</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2209600833</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-419326ac45ba9454d4a6dcd93f6582abeec944f0a9aad7f9c850f040787294d03</originalsourceid><addsrcrecordid>eNp9kctu1DAUhiMEolXpC7BAltiwCTi-JPEGaVoorVTEgrK2zjjOjKvEDj7OoHkM3rgOU0phgTe-fec_l78oXlb0bUV5-w5FJVVb0kqVgglWlfJJccyokCXjjD19dD4qThFvaV6SKVGp58URp6qpqRDHxc8rb6IFdH5DpgFwBLL6sPp887XiBExyO5f2xCEBxGAcJNuRHy5tyeWZXW0I2hhM8Dsb0QVPnCdmG4N3hmztBMmlHHlGlpP1CUk3xyWPJHsLEUnoSX62BnYukpSrSGO-vyie9TCgPb3fT4pvFx9vzi_L6y-frs5X16URjUhlboSzGoyQa1BCik5A3ZlO8b6WLYO1tUYJ0VNQAF3TK9NK2lNBm7bJU-goPyneH3SneT3azuTUEQY9RTdC3OsATv_9491Wb8JO1yIPvm6zwJt7gRi-zxaTHh0aOwzgbZhRM0ZVTWnLeUZf_4Pehjn63N5CNarltagzxQ6UiQEx2v6hmIrqxXR9MF1n0_Uv07XMQa8et_EQ8tviDPADgNMyfRv_5P6P7B2LRLnA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2207983646</pqid></control><display><type>article</type><title>Increasing plasma ADAMTS13 activity is associated with HBeAg seroconversion in chronic hepatitis B patients during 5 years of entecavir treatment</title><source>Publicly Available Content Database</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><source>Springer Nature - nature.com Journals - Fully Open Access</source><creator>Guo, Renyong ; Xie, Yirui ; Yang, Jiezuan ; Lu, Haifeng ; Ye, Ping ; Jin, Linfeng ; Lin, Wenqin</creator><creatorcontrib>Guo, Renyong ; Xie, Yirui ; Yang, Jiezuan ; Lu, Haifeng ; Ye, Ping ; Jin, Linfeng ; Lin, Wenqin</creatorcontrib><description>The relationship between hemostatic system and HBeAg seroconversion (SC) of chronic hepatitis B (CHB) patients is ill-defined. We therefore evaluate the predictive value of plasma ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin motif repeats 13) and VWF (von Willebrand factor) for CHB patients during 5-year entecavir (ETV) treatment. One hundred and fourteen HBeAg positive CHB patients on continuous ETV treatment were recruited. Liver biopsies were evaluated using the METAVIR scoring system, and plasma ADAMTS13 activity (ADAMTS13: AC) and VWF antigen (VWF: Ag) were determined at baseline, 3, 12, 24, 36, and 60 months, respectively. ETV treatment resulted in an increased ADAMTS13: AC and decreased VWF: Ag (both
P
< 0.001) in CHB patients. Cox multivariate analysis demonstrated that the change of ADAMTS13: AC after 1-year ETV treatment was an independent predictor for HBeAg SC at year 5. The area under the receiver operating characteristic (ROC) curve for the change of ADAMTS13: AC after 1-year ETV treatment plus baseline HBV DNA was 0.873 (
P
< 0.001) to predict SC at year 5. The results suggested that increased ADAMTS13: AC after 1 year ETV treatment was associated with a higher seroconversion, and could be used surrogate of HBeAg SC in CHB patients during 5-year ETV treatment.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/s41598-019-42421-5</identifier><identifier>PMID: 30976044</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>13/21 ; 14/63 ; 631/250/127/98 ; 692/308/53 ; 692/4020/4021/234 ; 96/21 ; ADAM protein ; ADAMTS13 Protein - genetics ; ADAMTS13 Protein - metabolism ; Adult ; Antiviral Agents - therapeutic use ; Antiviral drugs ; Deoxyribonucleic acid ; DNA ; Female ; Guanine - analogs & derivatives ; Guanine - therapeutic use ; Hepatitis ; Hepatitis B ; Hepatitis B e antigen ; Hepatitis B e Antigens - blood ; Hepatitis B e Antigens - immunology ; Hepatitis B virus - drug effects ; Hepatitis B virus - immunology ; Hepatitis B, Chronic - blood ; Hepatitis B, Chronic - drug therapy ; Hepatitis B, Chronic - immunology ; Humanities and Social Sciences ; Humans ; Interferon ; Liver ; Male ; multidisciplinary ; Multivariate analysis ; Patients ; ROC Curve ; Science ; Science (multidisciplinary) ; Seroconversion ; Seroconversion - drug effects ; Thrombospondin ; Viral Load ; Von Willebrand factor</subject><ispartof>Scientific reports, 2019-04, Vol.9 (1), p.5916-5916, Article 5916</ispartof><rights>The Author(s) 2019</rights><rights>The Author(s) 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-419326ac45ba9454d4a6dcd93f6582abeec944f0a9aad7f9c850f040787294d03</citedby><cites>FETCH-LOGICAL-c474t-419326ac45ba9454d4a6dcd93f6582abeec944f0a9aad7f9c850f040787294d03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2207983646/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2207983646?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30976044$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Guo, Renyong</creatorcontrib><creatorcontrib>Xie, Yirui</creatorcontrib><creatorcontrib>Yang, Jiezuan</creatorcontrib><creatorcontrib>Lu, Haifeng</creatorcontrib><creatorcontrib>Ye, Ping</creatorcontrib><creatorcontrib>Jin, Linfeng</creatorcontrib><creatorcontrib>Lin, Wenqin</creatorcontrib><title>Increasing plasma ADAMTS13 activity is associated with HBeAg seroconversion in chronic hepatitis B patients during 5 years of entecavir treatment</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><addtitle>Sci Rep</addtitle><description>The relationship between hemostatic system and HBeAg seroconversion (SC) of chronic hepatitis B (CHB) patients is ill-defined. We therefore evaluate the predictive value of plasma ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin motif repeats 13) and VWF (von Willebrand factor) for CHB patients during 5-year entecavir (ETV) treatment. One hundred and fourteen HBeAg positive CHB patients on continuous ETV treatment were recruited. Liver biopsies were evaluated using the METAVIR scoring system, and plasma ADAMTS13 activity (ADAMTS13: AC) and VWF antigen (VWF: Ag) were determined at baseline, 3, 12, 24, 36, and 60 months, respectively. ETV treatment resulted in an increased ADAMTS13: AC and decreased VWF: Ag (both
P
< 0.001) in CHB patients. Cox multivariate analysis demonstrated that the change of ADAMTS13: AC after 1-year ETV treatment was an independent predictor for HBeAg SC at year 5. The area under the receiver operating characteristic (ROC) curve for the change of ADAMTS13: AC after 1-year ETV treatment plus baseline HBV DNA was 0.873 (
P
< 0.001) to predict SC at year 5. The results suggested that increased ADAMTS13: AC after 1 year ETV treatment was associated with a higher seroconversion, and could be used surrogate of HBeAg SC in CHB patients during 5-year ETV treatment.</description><subject>13/21</subject><subject>14/63</subject><subject>631/250/127/98</subject><subject>692/308/53</subject><subject>692/4020/4021/234</subject><subject>96/21</subject><subject>ADAM protein</subject><subject>ADAMTS13 Protein - genetics</subject><subject>ADAMTS13 Protein - metabolism</subject><subject>Adult</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Antiviral drugs</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>Female</subject><subject>Guanine - analogs & derivatives</subject><subject>Guanine - therapeutic use</subject><subject>Hepatitis</subject><subject>Hepatitis B</subject><subject>Hepatitis B e antigen</subject><subject>Hepatitis B e Antigens - blood</subject><subject>Hepatitis B e Antigens - immunology</subject><subject>Hepatitis B virus - drug effects</subject><subject>Hepatitis B virus - immunology</subject><subject>Hepatitis B, Chronic - blood</subject><subject>Hepatitis B, Chronic - drug therapy</subject><subject>Hepatitis B, Chronic - immunology</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Interferon</subject><subject>Liver</subject><subject>Male</subject><subject>multidisciplinary</subject><subject>Multivariate analysis</subject><subject>Patients</subject><subject>ROC Curve</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><subject>Seroconversion</subject><subject>Seroconversion - drug effects</subject><subject>Thrombospondin</subject><subject>Viral Load</subject><subject>Von Willebrand factor</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNp9kctu1DAUhiMEolXpC7BAltiwCTi-JPEGaVoorVTEgrK2zjjOjKvEDj7OoHkM3rgOU0phgTe-fec_l78oXlb0bUV5-w5FJVVb0kqVgglWlfJJccyokCXjjD19dD4qThFvaV6SKVGp58URp6qpqRDHxc8rb6IFdH5DpgFwBLL6sPp887XiBExyO5f2xCEBxGAcJNuRHy5tyeWZXW0I2hhM8Dsb0QVPnCdmG4N3hmztBMmlHHlGlpP1CUk3xyWPJHsLEUnoSX62BnYukpSrSGO-vyie9TCgPb3fT4pvFx9vzi_L6y-frs5X16URjUhlboSzGoyQa1BCik5A3ZlO8b6WLYO1tUYJ0VNQAF3TK9NK2lNBm7bJU-goPyneH3SneT3azuTUEQY9RTdC3OsATv_9491Wb8JO1yIPvm6zwJt7gRi-zxaTHh0aOwzgbZhRM0ZVTWnLeUZf_4Pehjn63N5CNarltagzxQ6UiQEx2v6hmIrqxXR9MF1n0_Uv07XMQa8et_EQ8tviDPADgNMyfRv_5P6P7B2LRLnA</recordid><startdate>20190411</startdate><enddate>20190411</enddate><creator>Guo, Renyong</creator><creator>Xie, Yirui</creator><creator>Yang, Jiezuan</creator><creator>Lu, Haifeng</creator><creator>Ye, Ping</creator><creator>Jin, Linfeng</creator><creator>Lin, Wenqin</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20190411</creationdate><title>Increasing plasma ADAMTS13 activity is associated with HBeAg seroconversion in chronic hepatitis B patients during 5 years of entecavir treatment</title><author>Guo, Renyong ; Xie, Yirui ; Yang, Jiezuan ; Lu, Haifeng ; Ye, Ping ; Jin, Linfeng ; Lin, Wenqin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-419326ac45ba9454d4a6dcd93f6582abeec944f0a9aad7f9c850f040787294d03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>13/21</topic><topic>14/63</topic><topic>631/250/127/98</topic><topic>692/308/53</topic><topic>692/4020/4021/234</topic><topic>96/21</topic><topic>ADAM protein</topic><topic>ADAMTS13 Protein - genetics</topic><topic>ADAMTS13 Protein - metabolism</topic><topic>Adult</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Antiviral drugs</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>Female</topic><topic>Guanine - analogs & derivatives</topic><topic>Guanine - therapeutic use</topic><topic>Hepatitis</topic><topic>Hepatitis B</topic><topic>Hepatitis B e antigen</topic><topic>Hepatitis B e Antigens - blood</topic><topic>Hepatitis B e Antigens - immunology</topic><topic>Hepatitis B virus - drug effects</topic><topic>Hepatitis B virus - immunology</topic><topic>Hepatitis B, Chronic - blood</topic><topic>Hepatitis B, Chronic - drug therapy</topic><topic>Hepatitis B, Chronic - immunology</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Interferon</topic><topic>Liver</topic><topic>Male</topic><topic>multidisciplinary</topic><topic>Multivariate analysis</topic><topic>Patients</topic><topic>ROC Curve</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><topic>Seroconversion</topic><topic>Seroconversion - drug effects</topic><topic>Thrombospondin</topic><topic>Viral Load</topic><topic>Von Willebrand factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Guo, Renyong</creatorcontrib><creatorcontrib>Xie, Yirui</creatorcontrib><creatorcontrib>Yang, Jiezuan</creatorcontrib><creatorcontrib>Lu, Haifeng</creatorcontrib><creatorcontrib>Ye, Ping</creatorcontrib><creatorcontrib>Jin, Linfeng</creatorcontrib><creatorcontrib>Lin, Wenqin</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Guo, Renyong</au><au>Xie, Yirui</au><au>Yang, Jiezuan</au><au>Lu, Haifeng</au><au>Ye, Ping</au><au>Jin, Linfeng</au><au>Lin, Wenqin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Increasing plasma ADAMTS13 activity is associated with HBeAg seroconversion in chronic hepatitis B patients during 5 years of entecavir treatment</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><addtitle>Sci Rep</addtitle><date>2019-04-11</date><risdate>2019</risdate><volume>9</volume><issue>1</issue><spage>5916</spage><epage>5916</epage><pages>5916-5916</pages><artnum>5916</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>The relationship between hemostatic system and HBeAg seroconversion (SC) of chronic hepatitis B (CHB) patients is ill-defined. We therefore evaluate the predictive value of plasma ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin motif repeats 13) and VWF (von Willebrand factor) for CHB patients during 5-year entecavir (ETV) treatment. One hundred and fourteen HBeAg positive CHB patients on continuous ETV treatment were recruited. Liver biopsies were evaluated using the METAVIR scoring system, and plasma ADAMTS13 activity (ADAMTS13: AC) and VWF antigen (VWF: Ag) were determined at baseline, 3, 12, 24, 36, and 60 months, respectively. ETV treatment resulted in an increased ADAMTS13: AC and decreased VWF: Ag (both
P
< 0.001) in CHB patients. Cox multivariate analysis demonstrated that the change of ADAMTS13: AC after 1-year ETV treatment was an independent predictor for HBeAg SC at year 5. The area under the receiver operating characteristic (ROC) curve for the change of ADAMTS13: AC after 1-year ETV treatment plus baseline HBV DNA was 0.873 (
P
< 0.001) to predict SC at year 5. The results suggested that increased ADAMTS13: AC after 1 year ETV treatment was associated with a higher seroconversion, and could be used surrogate of HBeAg SC in CHB patients during 5-year ETV treatment.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>30976044</pmid><doi>10.1038/s41598-019-42421-5</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2045-2322 |
| ispartof | Scientific reports, 2019-04, Vol.9 (1), p.5916-5916, Article 5916 |
| issn | 2045-2322 2045-2322 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6459868 |
| source | Publicly Available Content Database; PubMed Central; Free Full-Text Journals in Chemistry; Springer Nature - nature.com Journals - Fully Open Access |
| subjects | 13/21 14/63 631/250/127/98 692/308/53 692/4020/4021/234 96/21 ADAM protein ADAMTS13 Protein - genetics ADAMTS13 Protein - metabolism Adult Antiviral Agents - therapeutic use Antiviral drugs Deoxyribonucleic acid DNA Female Guanine - analogs & derivatives Guanine - therapeutic use Hepatitis Hepatitis B Hepatitis B e antigen Hepatitis B e Antigens - blood Hepatitis B e Antigens - immunology Hepatitis B virus - drug effects Hepatitis B virus - immunology Hepatitis B, Chronic - blood Hepatitis B, Chronic - drug therapy Hepatitis B, Chronic - immunology Humanities and Social Sciences Humans Interferon Liver Male multidisciplinary Multivariate analysis Patients ROC Curve Science Science (multidisciplinary) Seroconversion Seroconversion - drug effects Thrombospondin Viral Load Von Willebrand factor |
| title | Increasing plasma ADAMTS13 activity is associated with HBeAg seroconversion in chronic hepatitis B patients during 5 years of entecavir treatment |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T12%3A27%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Increasing%20plasma%20ADAMTS13%20activity%20is%20associated%20with%20HBeAg%20seroconversion%20in%20chronic%20hepatitis%20B%20patients%20during%205%20years%20of%20entecavir%20treatment&rft.jtitle=Scientific%20reports&rft.au=Guo,%20Renyong&rft.date=2019-04-11&rft.volume=9&rft.issue=1&rft.spage=5916&rft.epage=5916&rft.pages=5916-5916&rft.artnum=5916&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/s41598-019-42421-5&rft_dat=%3Cproquest_pubme%3E2209600833%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c474t-419326ac45ba9454d4a6dcd93f6582abeec944f0a9aad7f9c850f040787294d03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2207983646&rft_id=info:pmid/30976044&rfr_iscdi=true |